BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Biotron Limited Landmark HIV Trial Underway


9/29/2011 10:24:01 AM

Sydney, Australia: 29 September 2011: Australian drug development company Biotron Limited (ASX:BIT) has commenced a landmark phase 1b/2a proof-of-concept human trial of its lead HIV drug candidate, BIT225.

Eighteen HIV-positive, treatment-naive patients will be treated with the drug over 10 days. A further eight patients will be given a placebo and both groups will then have a 10 day drug-free follow up.

Biotron scientists have previously established that the oral drug is able to inhibit replication of the HIV virus in monocyte lineage cells, where until now the virus has been able to 'hide' from current drug treatments.

Biotron Managing Director Dr Michelle Miller said she was confident this trial would further demonstrate the ability of BIT225 to reduce HIV loads in HIV-infected reservoir cells.

She described the commencement of the HIV trial as a major milestone for the Company and its lead drug candidate, which has also recorded encouraging data in previous trials in healthy volunteers and Hepatitis C virus-infected patients. "Treatment and elimination of this virus reservoir remains a major therapeutic challenge globally," she added.

BIT225 represents an extremely promising first-in-class opportunity and its progress is being keenly followed by the international pharmaceutical industry and investors."

Dr Miller said that while current treatments have resulted in reduction of HIV levels in the body, they have not been effective in eliminating virus from underlying reservoirs.

"By specifically targeting HIV in reservoir cells, Biotron's BIT225 offers the potential to stop the on-going cycle of infection in the body," Dr Miller said.

BIT225 is synergistic with commonly used anti-retroviral therapies and, if successful, would potentially be used in conjunction with these treatments.

The trial is expected to be completed and results announced in the first quarter of 2012.

Enquiries:

Dr Michelle Miller

Managing Director

Biotron Limited

+61-2 9805 0488

mmiller@biotron.com.au

Rudi Michelson

Monsoon Communications

+61-3 9620 3333

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including influenza, Dengue and Hepatitis B.

About BIT225 and HIV

BIT225 represents a novel, first-in-class approach to the treatment of HIV. BIT225 specifically targets HIV in reservoir cells and represents an opportunity to attack HIV at its source in the body. Current HIV therapies have little or no effect on HIV in the underlying reservoir of infected cells where the virus 'hides' from the immune system. The market for HIV is very large, with the US market alone for HIV worth over US$3.3 billion per annum.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->